Clinical Trial Search

Primary: Maximum Observed Plasma (Peak) Drug Concentration (Cmax ) — 1078; 1111; 1045; 14.31 picograms per milliliter (pg/mL)

Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale

Primary: Area Under the Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC 0-t) — 1065; 1024 ng*hr/mL

Primary: Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) — 6; 10; 11; 0 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 0; 0; 0; 0 Participants

Primary: Minute Ventilation at 55mm Hg End Tidal CO2 (VE55) Under Hyperoxic Conditions on Day 21 — 20.2; 21.2; 26.7 L/min — p=<0.001

Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 9; 3; 7; 7 Participants

Primary: Incidence of Dose-limiting Toxicity (DLT) of Pembrolizumab and Trametinib Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0…

Primary: Adverse Events — 230; 217; 215; 169 adverse events

Primary: Determination of RP2D — 1000 mg

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0 participants

Primary: Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA. — 5; 5; 5; 6 participants

Primary: Co-primary PK Endpoint Cmax: Maximum Serum Concentration — 12761.4; 12259.8 ng/mL

Primary: Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAE's) And Withdrawals Due to AE's — 5; 6; 2; 4 Participants